Table 1 Baseline characteristics of the cohort A
Characteristic | Survivors (n = 289) | Non-survivors (n = 47) | p-value |
|---|---|---|---|
Male gender (%) | 77% | 94% | 0.009 |
Age (years) | 53 (42, 63) | 65 (56, 77) | <0.001 |
Race (%) | Â | Â | 0.66 |
Caucasian | 64% | 74% | Â |
African American | 15% | 11% | Â |
Hispanic | 18% | 13% | Â |
Other | 3% | 2% | Â |
Height (cm) | 175.0 (165.1, 180.3) | 175.0 (169.5, 183.0) | 0.14 |
Weight (kg) | 78.1 (65, 95.6) | 80.0 (63.0, 99.0) | 0.91 |
Serum Creatinine (mg/dl) | 0.90 (0.7, 1.2) | 1.10 (0.7, 1.5) | 0.035 |
Creatinine Clearence (ml/min) | 86.9 (61.0, 122) | 64.0 (42.9, 86.3) | <0.001 |
Pitt Bacteremia Score | 1 (0, 3) | 3 (2, 6) | <0.001 |
Charlson Comorbidity Index | 2 (1, 3) | 2 (2, 4) | 0.030 |
Guideline-recommended Vancomycin Dose Received (%) | 33% | 38% | 0.48 |
Dose adjusted for renal function (%) | 39% | 59% | 0.028 |
Vancomycin Started in Intensive Care Unit (%) | 34% | 83% | <0.001 |
Initial Vancomycin Dose (mg/kg/day) | 24.9 (19.6, 30.4) | 21.0 (17.0, 29.0) | 0.036 |
Nephrotoxins (%) | Â | Â | Â |
Intravenous Contrast | 34% | 13% | 0.004 |
Aminoglycosides | 19% | 19% | 0.98 |
Vasopressors | 7% | 36% | <0.001 |
Infection source (%) | Â | Â | <0.001 |
Bloodstream catheter-related | 18% | 36% | Â |
Central nervous system | 0.4% | 0% | Â |
Gastrointestinal | 0.7% | 0% | Â |
Osteomyelitis | 0.7% | 4% | Â |
Pulmonary | 15% | 36% | Â |
Skin/muscle | 36% | 6% | Â |
Other | 20% | 17% | Â |